XML 121 R48.htm IDEA: XBRL DOCUMENT
v3.22.1

Asset Acquisitions - Additional Information (Details) - USD ($) |  | 1 Months Ended | 12 Months Ended
--- | --- | --- | ---
Jul. 20, 2021 | Jul. 31, 2021 | Mar. 31, 2021 | Nov. 30, 2020 | Dec. 31, 2021 | Dec. 31, 2020
Asset Acquisitions [Line Items] |  |  |  |  |  |
In-process research and development |  |  |  |  | $ 10,848,000 | $ 71,745,000
Common Stock |  |  |  |  |  |
Asset Acquisitions [Line Items] |  |  |  |  |  |
Convertible preferred stock converted into shares of common stock |  |  |  |  | 71,263,685 |
Common Stock | IPO |  |  |  |  |  |
Asset Acquisitions [Line Items] |  |  |  |  |  |
Convertible preferred stock converted into shares of common stock | 71,263,685 | 71,263,685 |  |  |  |
Asana Merger Agreement |  |  |  |  |  |
Asset Acquisitions [Line Items] |  |  |  |  |  |
Upfront payment made |  |  |  | $ 20,000,000.0 |  |
Future development and regulatory milestone cash payments maximum |  |  |  | $ 90,000,000.0 |  |
Additional shares required to issue upon achieving development milestone |  |  |  | 3,888,889 |  |
In-process research and development |  |  |  |  | $ 0 | 50,000,000.0
Milestones accrued |  |  |  |  | 0 | 0
Asana Merger Agreement | Series B-2 Convertible Preferred Stock |  |  |  |  |  |
Asset Acquisitions [Line Items] |  |  |  |  |  |
Shares issued |  |  |  | 4,000,000 |  |
Value per share |  |  |  | $ 7.50 |  |
Total fair value |  |  |  | $ 30,000,000.0 |  |
Asana Merger Agreement | Series B-2 Convertible Preferred Stock | Common Stock | IPO |  |  |  |  |  |
Asset Acquisitions [Line Items] |  |  |  |  |  |
Convertible preferred stock converted into shares of common stock |  |  |  | 3,333,333 |  |
ELS Purchase Agreement |  |  |  |  |  |
Asset Acquisitions [Line Items] |  |  |  |  |  |
Upfront payment made |  |  | $ 2,000,000.0 |  |  |
In-process research and development |  |  |  |  | $ 3,700,000 | $ 0
ELS Purchase Agreement | Common Stock |  |  |  |  |  |
Asset Acquisitions [Line Items] |  |  |  |  |  |
Shares issued |  |  | 500,000 |  |  |
Value per share |  |  | $ 3.36 |  |  |
Total fair value |  |  | $ 1,700,000 |  |  |

X
- Definition Additional shares required to issue upon achieving development milestone. + References No definition available. + Details
Name: | eras_AdditionalSharesRequiredToIssueUponAchievingDevelopmentMilestone
Namespace Prefix: | eras_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Asset acquisitions. + References No definition available. + Details
Name: | eras_AssetAcquisitionsLineItems
Namespace Prefix: | eras_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Future development and regulatory milestone cash payments maximum. + References No definition available. + Details
Name: | eras_FutureDevelopmentAndRegulatoryMilestoneCashPaymentsMaximum
Namespace Prefix: | eras_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Milestones accrued. + References No definition available. + Details
Name: | eras_MilestonesAccrued
Namespace Prefix: | eras_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Upfront payment made. + References No definition available. + Details
Name: | eras_UpfrontPaymentMade
Namespace Prefix: | eras_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(4) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number of shares of equity interests issued or issuable to acquire entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(4) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionSharePrice
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentInProcess
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of shares issued during the period as a result of the conversion of convertible securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-30) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 1E -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=eras_AsanaMergerAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=eras_SeriesB2ConvertiblePreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=eras_EmergeLifeSciencesPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |